retatrutide approval 2025 Promises Big Weight Loss, but Safety Remains a Question Demand for Unapproved Weight-Loss Drug

Current clinical programs are investigating how microdosing GLP-1s may help treat early metabolic dysfunction (like in perimenopause) and help minimize the common side effects associated with higher doses

Research from 2023 found that people lost Two popular GLP-1 medications, Ozempic and Mounjaro (tirzepatide), only have FDA approval for the management of type 2 diabetes

Medicaid covers GLP-1 medications but whats covered depends heavily on why you need one

Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes, have emerged as promising candidates due to effects on intake regulation and reward processing

Colace Osmotic vs